Molecular diagnosis of glycogen storage disease type IX using a glycogen storage disease gene panel.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 16 08 2019
revised: 20 03 2020
accepted: 28 03 2020
pubmed: 4 4 2020
medline: 30 12 2020
entrez: 4 4 2020
Statut: ppublish

Résumé

Glycogen storage disease type IX (GSD IX) is caused by a deficiency of hepatic phosphorylase kinase. The aim of this study was to clarify the clinical features, long term outcomes, and genetic analysis of GSD IX in Korea. A GSD gene panel was created and hybridization capture-based next-generation sequencing was performed. We investigated clinical laboratory data, results of molecular genetic analysis, liver biopsy findings, and long-term outcomes. Ten children were diagnosed with GSD IX at Seoul National University Children's Hospital. Hypoglycemia, hyperlactacidemia, hypertriglyceridemia, hyperuricemia, liver fibrosis on liver biopsy, and short stature was found in 30%, 56%, 100%, 60%, 80% and 50% of the children, respectively. Seven PHKA2 variants were identified in eight children with GSD IXa-one nonsense (c.2268dupT; p.(Asp757Ter)), two splicing (c.918+1G > A, c.718-2A > G), one frameshift (c.405_419delinsTCCTGGCC; p.(Asp136ProfsTer11)), and three missense variants (c.3628G > A; p.(Gly1210Arg), c.1245G > T and c.2746C > T; p.(Arg916Trp)). Two variants of PHKG2 were identified in two children with GSD IXc-one frameshift (c.783delC; p.(Ser262AlafsTer6)) and one missense (c.661G > A; p.(Val221Met)). Elevated liver enzymes and hypertriglyceridemia in children with GSD IXa tended to improve with age. For the first time, we report hepatocellular carcinoma in a patient with GSD IXc. The GSD gene panel is a useful diagnostic tool to confirm GSD IX. The clinical phenotype of GSD IXc is severe and monitoring for the development of hepatocellular carcinoma should be implemented.

Identifiants

pubmed: 32244026
pii: S1769-7212(19)30557-9
doi: 10.1016/j.ejmg.2020.103921
pii:
doi:

Substances chimiques

PHKA2 protein, human EC 2.7.1.19
Phosphorylase Kinase EC 2.7.1.19

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103921

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Authors have no relevant financial relationships to disclose or conflicts of interest.

Auteurs

Tae Hyeong Kim (TH)

Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.

Kwang Yeon Kim (KY)

Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.

Man Jin Kim (MJ)

Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Moon-Woo Seong (MW)

Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Sung Sup Park (SS)

Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Jin Soo Moon (JS)

Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.

Jae Sung Ko (JS)

Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: kojs@snu.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH